menu
    • menu
    [{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Cadila Pharmaceuticals | Wellcome Trust | Canadian Institutes of Health Research | Heart and Stroke Foundation Ontario","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Chlorothiazide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Population Health Research Institute \/ Cadila Pharmaceuticals | Wellcome Trust | Canadian Institutes of Health Research | Heart and Stroke Foundation Ontario","highestDevelopmentStatusID":"10","companyTruncated":"Population Health Research Institute \/ Cadila Pharmaceuticals | Wellcome Trust | Canadian Institutes of Health Research | Heart and Stroke Foundation Ontario"}]

    Find Clinical Drug Pipeline Developments & Deals for Chlorothiazide

    Menu

    Chlorothiazide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Population Health Research Institute

                            Country arrow
                            Pharmtech Exhibition
                            Not Confirmed

                            Population Health Research Institute

                            Country arrow
                            Pharmtech Exhibition
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorothiazide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Cadila Pharmaceuticals | Wellcome Trust | Canadian Institutes of Health Research | Heart and Stroke Foundation Ontario

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The International Polycap Study 3 (TIPS-3)

                            Details : Thiazide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cardiovascular Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 20, 2012

                            Lead Product(s) : Chlorothiazide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Cadila Pharmaceuticals | Wellcome Trust | Canadian Institutes of Health Research | Heart and Stroke Foundation Ontario

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth